Do you want to read an article? Please log in or register.
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
Breast Cancer
RECOMMENDED
Related content
Breast Cancer
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial
Ann Oncol
Harbeck N, Modi S, Pusztai L, Ohno S, Wu J, Kim SB, Yoshida A, Fabi A, Cao X, Joseph R, Li R, Żurawski B, Escrivá-de-Romaní S, Meneguetti R, Supavavej A, Chen SC, Liu Z, Kelly C, Curigliano G, Symmans WF, Gufran M, Ke J, Konpa A, Herbolsheimer P, Boileau JF, DESTINY-Breast11 Trial Investigators
doi: 10.1016/j.annonc.2025.10.019
ESMO 2025
Breast Cancer
LBA1: DESTINY-Breast05: T-DXd significantly improves IDFS and DFS versus T-DM1 in HER2-positive early breast cancer with residual invasive disease
Breast Cancer
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
N Engl J Med
Geyer CE Jr, Untch M, Huang CS, Mano MS, Mamounas EP, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, D'Hondt V, Conlin AK, Guarneri V, Wapnir IL, Jackisch C, Arce-Salinas C, Fasching PA, DiGiovanna MP, Crown JP, Wuelfing P, Shao Z, Rota Caremoli E, Bonnefoi HR, Hennessy BT, Stamatovic L, Castro-Salguero H, Brufsky AM, Knott A, Siddiqui A, Lambertini C, Boulet T, Nyawira B, Restuccia E, Loibl S, KATHERINE Study Group
doi: 10.1056/NEJMoa2406070
ESMO 2025
Breast Cancer
DESTINY-Breast11: Neoadjuvant T-DXd plus THP significantly improves pCR in high-risk HER2-positive early breast cancer
SABCS 2025
Breast Cancer
DESTINY-Breast11: T-DXd followed by THP shows manageable and more favorable safety profile versus ddAC–THP in patients with high-risk HER2-positive early breast cancer
Breast Cancer
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
Ann Oncol
Saura C, Cortés J, Modi S, Kim SB, Hamilton E, Hurvitz SA, Krop IE, Curigliano G, Iwata H, Im SA, Herbolsheimer P, Karnoub M, Boran A, Kuwahara Y, Egorov A, André F
doi: 10.1016/j.annonc.2025.11.007
Breast Cancer
Fourth Swiss Annual Meeting on HER2-Positive Breast Cancer: Antibody-Drug Conjugates in HER2-Positive Disease and Beyond
healthbook TIMES Onco Hema
Vetter M, Kurzeder C
doi: 10.36000/HBT.OH.2025.24.183
ESMO 2025
Breast Cancer
monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer
RECOMMENDED
Breast Cancer
Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Cancer Treat Rev
Nakatani S, Hayashi T, Yamamoto K, Maeda H
doi: 10.1016/j.ctrv.2025.102923